

APAS® PRESENTED AT AUSTRALIAN PHARMACEUTICAL CONFERENCE

2023 PDA Asia Pacific Regulatory Conference, Melbourne, Victoria, 28-29 November 2023

Adelaide, Australia, 30 November 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the Company's Quality and Regulatory Director, Mrs Julie Winson, presented the Company's APAS® technology at the 2023 Parental Drug Association (**PDA**) Asia Pacific Regulatory Conference held in Melbourne, Victoria (28-29 November 2023).

Key Points:

- **APAS® PharmaQC presented as a case study for artificial intelligence in pharmaceutical manufacturing**
- **Discussed evidence needed to implement APAS® PharmaQC as an alternative to manual plate reading**

The PDA Asia Pacific Regulatory Conference brings together the regions' industry experts and thought leaders to share their experiences and learn about the new regulations and technologies impacting pharmaceutical manufacturing. The Company's APAS® technology was selected as a case study for the implementation of artificial intelligence within the highly regulated pharmaceutical manufacturing market.

The Company's Quality and Regulatory Director, Mrs Winson, shared lessons learned achieving global regulatory clearances for the APAS® Independence as an In-Vitro Diagnostic device and discussed how these can be applied to support the latest application of the APAS® technology for environmental monitoring during pharmaceutical sterile manufacturing (**APAS® PharmaQC**).

LBT Quality and Regulatory Director, Mrs Winson said:

"We have led the way in the application of artificial intelligence technology for clinical microbiology and remain one of only five devices using artificial intelligence to obtain clearance by the US FDA in this field.¹ The systems and processes we have developed for our clinical product are a key differentiator for our technology and enable us to collect the data we require to demonstrate the performance of APAS PharmaQC in pharmaceutical environmental monitoring."

The conference presentation can be read in full on the LBT website: <https://www.lbtinnovations.com/case-study-artificial-intelligence-for-environmental-monitoring/>

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com

¹ U.S. Food & Drug Administration Website, Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices, <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-ai-ml-enabled-medical-devices>